Pharma Jonpi . / 1.1 / .
07 octubre 2024
ATEZOLIZUMAB - NEUROTOXICITY Is Challenging To Recognize Due To Widely Varying Symptoms, Emphasizing The Need For a Thorough Safety Assessment To Determine The Incidence And Patient Risk Profiles .
‹
›
Inicio
Ver versión web